GleamWall
中文EN

KTTA Pasithea Therapeutics Corp.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1841330 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-84.0%
TTM EPS YoY68.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-88.8%
ROA-82.6%
ROIC (approx.)-414.6%
Asset turnover—

Leverage & solvency

Liabilities / assets5.9%
Debt / equity0.00x
Current ratio15.67x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-18.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$4.46M$3.69M$2.94M$2.74M$1.36M$2.15M$1.73M$1.51M
SG&A expense$2.51M$2.03M$1.93M$7.51M$1.75M$1.66M$1.95M$1.75M
Operating income-$6.97M-$5.71M-$4.88M-$10.26M-$3.11M-$3.81M-$3.68M-$3.26M
Pretax income-$6.58M-$5.27M-$2.87M-$10.11M-$3.04M-$3.72M-$3.56M-$3.18M
Net income-$6.58M-$5.27M-$2.87M-$10.11M-$3.04M-$3.72M-$3.56M-$3.18M
EBITDA———-$10.26M-$3.09M-$3.81M-$3.68M-$3.25M
EPS (basic)-0.20-0.16-0.12—-0.41-0.66-1.61—
EPS (diluted)-0.20-0.16-0.12—-0.41-0.66-1.61—
Weighted avg. shares (diluted)33.41M32.10M24.34M—7.44M5.64M2.21M—
Balance sheet
Cash & equivalents$41.22M$45.66M$50.40M$55.16M$4.12M$7.22M$5.34M$6.92M
Current assets$43.18M$48.24M$52.73M$56.46M$5.53M$8.64M$6.12M$7.37M
PP&E, net—————$113,564$117,522$122,343
Goodwill————$1.26M$1.26M$1.26M$1.26M
Intangibles$3.31M$3.47M$3.62M$2.90M$6.84M$7.00M$7.15M$7.31M
Total assets$46.49M$51.71M$56.35M$60.24M$13.63M$17.01M$14.66M$16.06M
Current liabilities$2.76M$1.84M$1.49M$4.97M$1.38M$1.74M$1.59M$1.12M
Total liabilities$2.76M$1.87M$1.54M$5.02M$1.42M$1.83M$1.68M$1.28M
Shareholders' equity$43.73M$49.84M$54.80M$55.22M$12.21M$15.18M$12.98M$14.78M
Shares outstanding33.41M33.41M24.94M23.09M7.44M7.44M2.71M1.39M
Cash flow statement
Operating cash flow-$4.48M-$4.71M-$4.79M-$5.40M-$2.89M-$3.87M-$3.06M-$2.44M
Financing cash flow$0$8,476$750$56.42M-$116,145$5.74M$1.47M-$23,550
Depreciation & amortization———$421$24,000$4,000$4,821$4,717
Stock-based compensation$435,000$329,000$139,182$88,277$53,000$58,000$98,558$118,383

Free plan shows the latest 8 periods; Pro shows all 24 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.